-       Report 
   - May 2025
    -  240 Pages 
    Global
   
   From       €4306EUR$4,799USD£3,779GBP 
                -       Report 
   - January 2025
    -  153 Pages 
    Global
   
   From       €5339EUR$5,950USD£4,686GBP 
                  -       Report 
   - October 2025
    -  188 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                -       Report 
   - November 2025
    -  264 Pages 
    Global
   
   From       €5249EUR$5,850USD£4,607GBP 
                  -       Drug Pipelines 
   - April 2025
    -  240 Pages 
    Global
   
   From       €2154EUR$2,400USD£1,890GBP 
      €2692EUR$3,000USD£2,363GBP 
                   -       Report 
   - May 2025
    -  141 Pages 
    Global
   
   From       €2287EUR$2,549USD£2,008GBP 
      €2691EUR$2,999USD£2,362GBP 
                -       Report 
   - December 2024
    -  182 Pages 
    Global
   
   From       €4038EUR$4,500USD£3,544GBP 
                -       Report 
   - March 2025
    -  228 Pages 
    Global
   
   From       €2243EUR$2,500USD£1,969GBP 
                -       Report 
   - June 2025
    -  316 Pages 
    Global
   
   From       €3993EUR$4,450USD£3,505GBP 
                -       Report 
   - June 2025
    -  400 Pages 
    Global
   
   From       €4441EUR$4,949USD£3,898GBP 
                  -       Report 
   - August 2025
    -  190 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                -       Drug Pipelines 
   - June 2025
    -  200 Pages 
    Global
   
   From       €2503EUR$2,789USD£2,196GBP 
                -       Report 
   - June 2025
    -  130 Pages 
    Global
   
   From       €5339EUR$5,950USD£4,686GBP 
                  -       Report 
   - October 2025
    -  180 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                  -       Report 
   - October 2025
    -  191 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                  -       Report 
   - October 2025
    -  188 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                  -       Report 
   - August 2025
    -  193 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                  -       Report 
   - August 2025
    -  192 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                  -       Report 
   - August 2025
    -  188 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                  -       Report 
   - October 2025
    -  250 Pages 
    Global
   
   From       €4029EUR$4,490USD£3,536GBP 
             
          The Anti-Obesity Drugs market is a sector of the pharmaceutical industry that focuses on the development and sale of drugs designed to reduce or prevent obesity. These drugs are typically prescribed to individuals who are overweight or obese and are at risk of developing health complications due to their weight. Commonly prescribed anti-obesity drugs include orlistat, lorcaserin, and phentermine. These drugs work by suppressing appetite, increasing metabolism, or blocking the absorption of fat.
The    Anti-Obesity Drugs market is highly competitive, with many large pharmaceutical companies vying for market share. Some of the major players in the market include GlaxoSmithKline, Novo Nordisk, Sanofi, Pfizer, and Merck. These companies are constantly developing new drugs and treatments to meet the needs of their customers. Show Less   Read more